Amyris Highlights Progress in Total and Cosan Partnerships

Amyris Highlights Progress in Total and Cosan Partnerships

Focused Execution Supported by Leading Partnerships and Investment Commitments

EMERYVILLE, Calif., April 1, 2013 (GLOBE NEWSWIRE) -- Amyris, Inc.
(Nasdaq:AMRS), a leading renewable chemicals and fuels company, announced
today three important milestones underscoring its continued, focused execution
with respect to its collaborations and partnerships.

1.Amyris has received confirmation Total (Paris:TOTF) will provide $30
    million of funding to Amyris by July 2013, as anticipated in the revised
    collaboration agreement announced last year. In addition, as a result of
    the continued success of Amyris's existing technology collaboration with
    Total, the two parties intend to form a joint venture company by mid-2013
    to market renewable diesel, jet fuel, and other specialty products derived
    from Biofene®, Amyris's renewable brand of farnesene.
2.Amyris and Cosan (NYSE:CZZ) have entered into definitive agreements to
    expand their joint venture, Novvi, to include renewable additives and
    finished lubricants for industrial, commercial and automotive uses in
    addition to the joint venture's original scope of renewable, base oils for
    such markets. Amyris plans to supply Biofene to Novvi for finishing into
    final products until the joint venture builds its own farnesene production
3.Amyris has met the technical milestones at its production plant in Brazil
    to satisfy the conditions for a follow-on common stock investment of $5
    million from its existing investor, Biolding Investment SA. The $5 million
    Amyris received last week represented the final tranche of Biolding's
    preexisting contractual obligation to fund $15 million upon satisfaction
    of certain performance conditions at Amyris's Biofene plant.

"Amyris is delivering on a track-record of focused execution and
collaboration. We continue to meet or exceed the technical milestones for our
collaboration with Total and work closely to commercialize products under the
Amyris-Total fuels joint venture," said John Melo, Amyris President & Chief
Executive Officer.

"With Cosan, we have expanded the scope of our joint venture's product
portfolio beyond base oils to a range of industrial, commercial, and
automotive additives and lubricants derived from Biofene. And, thanks to the
successful performance of our first industrial-scale farnesene production
facility in Brazil, we met the conditions for an additional investment from
one of our leading stockholders," added Melo.

Further details about the terms and conditions of these agreements are
included in the relevant regulatory filings, including Amyris's annual report
on Form 10-K filed last week.

About Amyris, Inc.

Amyris is an integrated renewable products company focused on providing
sustainable alternatives to a broad range of petroleum-sourced products.
Amyris uses its industrial synthetic biology platform to convert plant sugars
into a variety of hydrocarbon molecules—flexible building blocks that can be
used in a wide range of products. Amyris's initial portfolio of commercial
products is based on Biofene, Amyris's brand of renewable farnesene, a
long-chain hydrocarbon. Amyris is commercializing these products both as No
Compromise® renewable ingredients in cosmetics, flavors and fragrances,
polymers, lubricants and consumer products, and also as No Compromise
renewable diesel and jet fuel. Amyris Brasil Ltda., a subsidiary of Amyris,
oversees the establishment and expansion of Amyris's production in Brazil.
More information about Amyris is available at

Forward-Looking Statements

This release contains forward-looking statements, and any statements other
than statements of historical facts could be deemed to be forward-looking
statements. These forward-looking statements include, among other things,
statements regarding future events (such as establishment of a joint venture
with Total by mid-2013, plans to supply Biofene to Novvi, the receipt of
collaboration funding, and commercializing products for a fuels joint venture)
that involve risks and uncertainties. These statements are based on
management's current expectations and actual results and future events may
differ materially due to risks and uncertainties, including those associated
with any delays or failures in development, production or commercialization of
products, liquidity and ability to fund capital expenditures, Amyris's
reliance on third parties to achieve its goals, and other risks detailed in
the "Risk Factors" section of Amyris's quarterly report on Form 10-K filed on
March 28, 2013. Amyris disclaims any obligation to update information
contained in these forward-looking statements whether as a result of new
information, future events, or otherwise.

Amyris, Biofene and No Compromise are trademarks or registered trademarks of
Amyris, Inc.

CONTACT: Media Contacts
         Joel Velasco
         +1 (510) 597-5577

company logo
Press spacebar to pause and continue. Press esc to stop.